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diarrhea, dyspnea, fatigue, insomnia, nausea, neuropathy, pain, and vomiting. The
final recommendations provide guidance on selection of PRO measures, imple-
mentation methods and data analysis/reporting considerations. CONCLUSIONS:
The patient perspective is an essential component of CER. Standardizing PRO data
collection in oncology trials will lead to greater comparability and improved pa-
tient-centered decision-making.
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EXAMINING KNOWLEDGE AND INFORMATION SEEKING BEHAVIORS TOWARDS
BLOOD TRANSFUSION AMONG INDIVIDUALS WITH CANCER
Naim A1, Gollins JR2, Reynolds C3, Walls D4
1Janssen Scientific Affairs, LLC, Horsham, PA, USA, 2Delta Modelling Group, Mount Prospect, IL,
USA, 3Benfield Group, Saint Louis, MO, USA, 4BDJ Solutions, Medford, MA, USA
OBJECTIVES: Examine knowledge and information seeking behaviors towards
blood transfusions among individuals with metastatic or recurrent cancer.
METHODS: An online survey was conducted from a nationally representative pa-
tient panel in 1Q2011. All respondents were 18 years and diagnosed with Cancer
by a physician. Participants were asked about their blood transfusion history, in-
formation seeking behaviors, and knowledge about blood transfusion. RESULTS: A
total of 206 individuals responded to survey. 65% (n133) were female and 25%
(n52) were over 55 years; 55% (n114) were anemic and 45% (92) not anemic. 62%
(n128) had received blood transfusion, whereas, 38% (n78) had no transfusions.
Top two sources of information are doctor (85%) and Internet (78%). Among those
previously transfused, 74% received right amount of information, whereas, 11%
received too little information, and 15% received toomuch information. More than
90% of transfused indicated they knew the reasons for and benefits of getting a
blood transfusion. Less than two-thirds received information about the costs. Over
65% of not transfused said that it is extremely important to know risks of infec-
tions, right blood type and screening techniques. Among previously transfused,
about 70% agreed that they made an informed choice about receiving blood trans-
fusions. Among the previously transfused, 78% agree that they knew the benefits
compared with 68% not transfused. About 68% of transfused and not transfused
agree they knew the risks of blood transfusion. CONCLUSIONS: Doctor’s office and
internet are primary sources of information about blood transfusions. Gaps in
knowledge exist about benefits, risks, and costs of blood transfusions. A significant
number feel that they need more information about blood transfusion to make an
informed choice. Providers should consider adopting shared-decisionmakingwith
their patients.
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OBJECTIVES: According to the FDA Patient-reported outcome (PRO) Guidance, ev-
idence of input from the appropriate population during the development of a PRO
measure is critical to determine whether a measure is applicable. A literature re-
view was conducted to identify the symptoms and impacts (concepts) of brain
metastases (BM) and the key PRO measures used in BM to compare their develop-
ment and content validity. METHODS: Literature searches were conducted using
MEDLINE®. PRO measures were reviewed for patient input and the concepts re-
ported in the clinical literature on patients with BM were compared to those in-
cluded in the identified PRO measures. RESULTS: A total of 34 concepts and seven
key PROmeasures used in BM (Functional Assessment of Cancer Therapy- General
[FACT-G], FACT-Brain Tumor [FACT-Br], FACT-Brain Symptom Index [FBrSI], Euro-
pean Organization for Research and Treatment of Cancer-Quality of Life Question-
naire [EORTC-QLQ-C30], EORTC-Brain cancer module [EORTC QLQ-BN20], the
EORTC- palliative care cancer module [EORTC QLQ-C15-PAL] and the M.D. Ander-
son Symptom Inventory-Brain Tumor Module [MDASI-BT]) were reviewed. The
major limitation of all measures reviewed is that the items of thesemeasures were
not developed based on qualitative interviews with BM patients. In addition, these
measures include concepts that were not related to BM per se as identified in the
literature (e.g. itchy skin); some concepts found in the literature were not included
in these instruments (e.g. dizziness). CONCLUSIONS: Review of the seven PRO
measures used in patients with BM found that none of the measures have docu-
mented patient input in their development. The gaps between concepts reported in
the literature and the PRO measures suggest the need for direct patient input in
development of suchmeasures in order to be comprehensive and yet specific to the
target population.
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OBJECTIVES: COMFORT-I is a Phase III randomized, double-blind, placebo-con-
trolled study of ruxolitinib in patients with myelofibrosis. The placebo arm pro-
vides a controlled setting to assess changes in symptomatic burden and other
patient-reported outcomes (PROs) among patients not receiving myelofibrosis
therapy. METHODS: A total of 154 patients with intermediate-2 or high-risk my-
elofibrosis were randomized to placebo after a 28-day washout of previous myelo-
fibrosis therapies. Using a Total Symptom Score (TSS), myelofibrosis symptoms
(night sweats, itching, abdominal discomfort, pain under ribs on left side, early
satiety, and bone/muscle pain) were measured using the modified Myelofibrosis
Symptom Assessment Form v2.0. Other PRO measures included the EORTC QLQ-
C30 (100-point scale), PROMIS Fatigue Scale (100-point scale), and Patient Global
Impression of Change (PGIC; 7-point scale: 1very much improved, 7very much
worse, 4no change). Patients who withdrew or crossed over to active treatment
before a study visit were not included in analyses for that visit or subsequent visits.
RESULTS: The study included 35% intermediate-2 and 65% high-risk patients (me-
dian 2.5 years since diagnosis). By week 24, mean TSS worsened by 42% from
baseline. EORTC QLQ-C30 Global Health Status and functional subscale scores also
worsened from baseline to week 24, with the greatest changes in Role Functioning
(mean change  -11.1) and Social Functioning (-9.0); mean PROMIS Fatigue score
worsened by 9.1%. Mean PGIC score was 4.2 at week 24; 40.2% of patients perceived
their condition to be worse and 29.9% unchanged. As measured by MRI/CT, spleen
volume (closely related to some myelofibrosis symptoms) increased by a mean of
8.1% at week 24. CONCLUSIONS: In concert with increased spleen volume, patients
reported worsening of myelofibrosis symptoms and other PROs over a 6-month
time frame in this placebo population. Recognition of the debilitating symptoms of
myelofibrosis and its progressive nature suggest early intervention with effective
therapy should be considered.
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OBJECTIVES: Although NSCLC is associated with substantial symptom burden and
significantly impacts patients’ health-related quality of life (HRQoL), published
data from routine care are scarce. Improving the understanding of the HRQoL
impact of NSCLC will allow to comprehend more in-depth the benefit of treat-
ments, palliative care and differing HRQOL accross health states. METHODS: A
total 315 patients were enrolled in Australia, Belgium, Canada, France, Italy, Swe-
den, Turkey, the Netherlands and the UK to complete the EQ-5D and EQ-VAS ques-
tionnaires after receiving current treatment for 6-8 weeks. In order not to influence
patients’ perceived health, patients completed the questionnaire prior to receiving
information on their tumor status. Patient demographic, disease history, treat-
ment and adverse event data was identified from the patient chart. Utilities were
calculated by applying the UK tariffs. Patients were stratified into 12 health states
based on treatment line and treatment response status. Patients included had
advanced stage (IIIb or IV) disease, were 18 years, received 1-4 lines of treatment
having an ECOG performance status of 0-2 (scale: 0-4 with 4 being bedridden).
RESULTS: Mean age at advanced NSCLC diagnosis was 64.5 years [SD9.97] with
61.8% of patients being male, and 80.3% with stage IV disease. Fifty-two percent,
27%, and 19% of patients were on 1st, 2nd, or 3rd/4th line, respectively. Patients with
progressive disease increased with treatment line; 15% (1st line), 27% (2nd line) and
46% (3rd/4th line).Meanutility in the overall samplewas 0.65 [SD0.31].Meanutility
for progression free patients on 1st, 2nd, and 3rd/4th line treatment was 0.71
[SD0.24], 0.72 [SD0.26], and 0.62 [SD0.46], respectively.Meanutility for patients
who progressed after 1st, 2nd and 3rd/4th line treatment was 0.68 [SD0.21], 0.59
[SD0.34] and 0.46 [SD0.38], respectively. CONCLUSIONS: Both line of treatment
and progressive NSCLC disease were found to impact patients’ HRQoL assessed
using EQ-5D derived utilities.
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OBJECTIVES: Meaningful improvement in symptoms and quality of life (QOL) are
important in treating patients with small cell lung cancer (SCLC). This analysis
assessed and evaluated minimally important differences (MIDs) on the Lung Can-
cer Symptom Scale (LCSS) for patients with amrubicin- or topotecan-treated SCLC.
METHODS: A prospective, multicenter, open-label, phase III randomized design
study of 637 patients compared efficacy and safety of amrubicin to topotecan in
treatment of SCLC. LCSS data were collected at baseline, day 1 of each cycle, and
study end. The LCSS contains six symptoms (appetite, cough, dyspnea, fatigue,
hemoptysis, pain), and three items (symptom distress, interference with activity
level, global QOL). To assess clinicallymeaningful change on LCSS symptoms,MIDs
were calculated as standard deviation change from baseline for each symptom
item; for Symptom Burden Index (SBI) and Total Score, 1 standard error of mea-
surement change from baseline was utilized to adjust for reliability in the SCLC
population. RESULTS: 532 subjects with baseline and post-baseline LCSS datawere
analyzed (mean age60.1; male 58.2%). Clinically relevant minimally important
symptom and QOLworsening were similar to studies in non-small cell lung cancer
(NSCLC). Minimal values for detecting clinically meaningful differences were: for
individual symptoms, 13.7–14.5, excluding hemoptysis (4.3); for SBI, 8.7; for Total
Score, 7.2. Patients on amrubicin experienced less deterioration in individual
symptoms, less overall symptom burden, and improved QOL. The proportions of
patients with clinically relevant deterioration in coughing favored amrubicin at
Cycles 2, 6, and study end (p0.0265, p0.0026, p0.0194, respectively); at Cycles 2
and 6, but not study end, deterioration in dyspnea favored amrubicin (p0.001,
p0.0419, respectively). Similar trends favoring amrubicin were seen in the re-
maining symptoms. CONCLUSIONS: Meaningful change on the LCSS, previously
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developed in NSCLC, has been established here in SCLC. Patients on amrubicin
experienced less symptom deterioration during treatment.
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OBJECTIVES: Gain insights into Health Technology Assessment (HTA) agencies
expectations regarding Health-Related Quality of Life (HRQoL) for cost-effective-
ness evaluations of new medications for treating Castration-Resistant Prostate
Cancer (CRPC). METHODS: In January 2012, 61 HTA agencies websites were
scanned to identify HTAs of newmedications for the treatment of CRPC published
from 2005 to present. Only those evaluating the cost-effectiveness of new technol-
ogies were retained and analyzed for a better understanding of HTA agencies’
expectations regarding HRQoL in CRPC. RESULTS: 39 HTAs were identified, 12 of
which are currently in progress. The 27 published reports comprised 12 technology
appraisals, 9 horizon scanning reports and 6 literature reviews. Only 9 of the 12
technology appraisals evaluated cost-effectiveness, these included seven apprais-
als on three drugs: IQWiG (Germany) assessed abiraterone; NICE (England &Wales)
accepted docetaxel and rejected cabazitaxel; SMC (Scotland) rejected docetaxel
and cabazitaxel; CVZ (Netherlands) accepted cabazitaxel; PBAC (Australia) ac-
cepted docetaxel after two rejections and rejected cabazitaxel. Uncertainty regard-
ing HRQoL measures was the most often cited negative comment. For both do-
cetaxel and cabazitaxel, the absence of quality of life measures from the main
phase III trials and uncertainty around utility values were cited as reasons for
rejection by NICE, SMC and PBAC. The CVZ accepted cabazitaxel for temporary
reimbursement on the understanding that further subpopulation analysis and
more data on utilities will be needed. The IQWiG assessment of abiraterone com-
mented on uncertainties regarding the validity of the QoL questionnaire and re-
strictions in subgroup analyses. CONCLUSIONS: Our review indicates the need to
include comprehensive quality of life measures in phase III trials for new drugs to
treat CRPC, ensure these can be mapped into robust utility values and conduct
meaningful CRPC subpopulation analyses. Further insights will be gained in the
near future with the publication of CRPC HTAs currently in progress.
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OBJECTIVES:Data collected using patient reported outcomes (PRO) tools in clinical
trials provide unique information about patients’ experience with their treatment.
One of the major challenges with conducting clinical trials in linguistically diverse
countries such as India, however, is identifying and using PRO scales that are
linguistically validated in most of the representative regional languages. Lack of
availability of linguistically validated scales can limit the participation of a relevant
population from clinical trials. Therefore, the objective of this study was to deter-
mine if the PRO instruments used in clinical trials are linguistically validated in
local languages across the various regions in India. For this study we limited our
therapeutic area focus to clinical trials conducted in oncology. METHODS: A de-
tailed review of the registered trials in clinicaltrials.gov was conducted using qual-
ity of life (QoL) and oncology as keywords. Identified articles (n103)were screened
to exclude trials where QoL was not measured and studies with n 	 30. ProQoLID
and official websites of questionnaires were used to determine the availability of
translations and linguistic validity of the questionnaires included in clinical trials.
RESULTS: EQ-5D is the most commonly used generic instrument in oncology trials
and is validated in most 11 Indian languages. EORTC-QLQC30, EORTC-QLQH&N35,
EORTC-QLQBR23 and EORTC-QLQLC13 are the most commonly used cancer spe-
cific instruments and are validated in approximately 10 Indian languages. None of
the generic or disease specific cancer instruments have been translated or linguis-
tically validated for the Eastern & North-Eastern regions in India in languages such
as Oriya, Santhali, Assamese, and Manipuri thereby limiting the participation of
patients from these regions in clinical trials. CONCLUSIONS: The results of our
analysis indicate that future efforts need to focus on translating and validating PRO
instruments in 14 different Indian languages that should include the North Eastern
regions of India.
CANCER – Health Care Use & Policy Studies
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OBJECTIVES: Antidepressants (ADs) are primarily used to treat depression and anxi-
ety among individuals with cancer and depression; however ADs are also being used
for symptomatic relief from hot-flashes, neuropathic-pain, and fatigue in this popu-
lation. Although there is a lack of robust evidence on the effectiveness of ADs in this
population, and conflicting reports of a possible association between AD use and risk
of recurrenceof certaincancersexists;ADsarestill beingprescribed in thispopulation.
Thus, the objective of this studywas to systematically review the extent of anyADuse
among individuals with cancer. METHODS: A systemic literature search was con-
ducted using 4 electronic databases (PubMed, CINHAL, PsychINFO, and Web-of-Sci-
ence), and cross-referencing. Studies starting from1975 to 2011, and fromall countries
were assessed. Eligibility criteria used for the extraction of studies included: 1)full
articles published in peer-reviewed journals in English-language only; 2)observational
studieswithdata onanyuse or prescription ofADs; and 3)adults and children aged1
year diagnosed with cancer (all types and stages of cancer were included). Studies on
the use of psychotropic agents other thanADs or psychotherapywere excluded. After
data extraction, number and percentages of individuals with cancer using ADs were
calculated.RESULTS:The search yielded 1880 studies, 14 ofwhichmet thepredefined
inclusion criteria. Overall, the rates of AD use ranged from 1%-26% in varying sub-
groupsof cancerpatients;with lower rates inpediatric cancerpatients (7%-12.3%), and
in those with advanced-stage cancers (7.4%-16%). Rates also varied according to the
type of cancers: breast (11.5%-34%), prostate (7%-18.8%), colon (7.5%-17.3%) and lung
(7.2%-13.7%). The rates were higher among individuals with cancer and clinically di-
agnosed depression (12%-66.6%). CONCLUSIONS: Our descriptive results suggest
that ADusemay be associatedwith cancer site and stage, and presence of clinically
diagnosed depression; and is lower in pediatric and advanced-stage cancer pa-
tients.
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OBJECTIVES: Hypomethylating agents (HMAs), decitabine and azacitidine, are in-
dicated for use in treatment of myelodysplastic syndromes (MDS), however only a
minority of patients receive HMAs. Our objective was to examine patterns of treat-
ment associated with FDA-approved 5-day decitabine (DEC-5) and 7-day azaciti-
dine (AZA-7) and off-label 5-day azacitidine (AZA-5) in MDS patients. METHODS:
We identified MDS patients with an initial HMA treatment between July 1, 2005 to
June 30, 2009 in 2 large insurance claims databases. Index date was the date of
initial HMA treatment. Patients were stratified into: DEC-5, AZA-7, or AZA-5, based
on their first cycle of treatment and were followed for 6 months. We described the
number of unique cycles of index treatment and treatment gaps (days of missed
treatment) in these groups. RESULTS:We identified 18,706 patients with MDS; 546
were treated with HMAs and were included in the study (156 received DEC-5, 176
received AZA-5 and 214 received AZA-7). Mean age was similar across groups:
68.8-71.2 years. Neutropenia was more common before treatment initiation in the
DEC-5 (34.6%) group than in AZA-5 (22.7%) and AZA-7 (26.6%; p.05) groups. There
were 1,701 treatment cycles: 431 DEC-5 (per patient mean:2.8; median:2), 586 for
AZA-5 (mean:3.3; median:3), and 684 for AZA-7 (mean:3.2; median:3) (p0.05 for
means). DEC-5 cycles had the fewest gaps: 94.9% had no treatment gaps, compared
to 89.1% for AZA-5 and 23.4% for AZA-7. Among DEC-5 cycles, 3.2% had a 2 day gap,
compared to 7.2% for AZA-5 and 66.5% for AZA-7 (p0.001). CONCLUSIONS: In this
retrospective claims analysis, few MDS patients were treated with HMAs. Among
those who received HMAs, decitabine patients were more likely to have prior neu-
tropenia. Between the 2 FDA-approved regimens, DEC-5 and AZA-7, there were
significantly fewer gaps with decitabine treatment. More treatment gaps were ob-
served with use of longer AZA regimen.
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OBJECTIVES: Comprised of carcinoid and pancreatic neuroendocrine tumors
(NETs), gastrointestinal NETs give rise to diverse clinical syndromes. Current treat-
ment guidelines lack some specificity. We summarize an expert panel consensus
on medical treatment of well-differentiated (grade 1-2) unresectable midgut NETs.
METHODS:ThemodifiedRAND/UCLADelphi processwas used to collectNET treat-
ment appropriateness ratings. The process involved recruitment of physician ex-
perts (e.g., by specialty, geography, practice), literature review, and collection of
ratings before and after a face-to-face discussion. Experts and moderator were
blinded to funding source. Patient scenarios were rated on a 1-9 scale on appropri-
ateness of various therapies and were labeled as appropriate, inappropriate, or
uncertain. Scenarios with2 ratings in 1-3 and2 in 7-9 range were considered to
have disagreement. RESULTS: Panelists (age: 38-63 years) were from northeast,
midwest, south, and west regions. Panelists had practiced for a mean 15.5 years
and reported seeing 25 to 800NETpatients per year. Panelists rated 202 scenarios in
midgut NETs. The proportion on which there was disagreement decreased from
11.7% (23 scenarios) before the meeting to 4.5% (9) after. After the meeting, 49% (99
scenarios) were rated inappropriate, 29.7% (60) were uncertain, and 16.8% (34) were
appropriate. Resulting consensus statements include: 1) it is appropriate to use
somatostatin analogs as 1st-line therapy in all patients; 2) it is appropriate to in-
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